Get started
Author

Erin L. O’Hearn

Observed names: E. OHearn, E. O’Hearn, Erin O'Hearn, Erin O’Hearn, O’Hearn, Erin
ORCID: 0009-0003-4113-4259
Observed ORCID: 0009-0003-4113-4259
OpenAlex ID: A5068714623
Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate
2016 · Catherine A. Evans, Tao Liu, et al. · ACS Medicinal Chemistry Letters · 154
Evaluation of Protein Kinase cAMP-Activated Catalytic Subunit Alpha as a Therapeutic Target for Fibrolamellar Carcinoma
2022 · Stefanie S. Schalm, Erin O’Hearn, et al. · Gastro Hep Advances · 21
PDF
STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20–Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer Models
2025 · Raymond A. Pagliarini, Jack A. Henderson, et al. · Clinical Cancer Research · 11
PDF
Discovery of STX-721, a Covalent, Potent, and Highly Mutant-Selective EGFR/HER2 Exon20 Insertion Inhibitor for the Treatment of Non-Small Cell Lung Cancer
2025 · Benjamin C. Milgram, Deanna R. Borrelli, et al. · Journal of Medicinal Chemistry · 9
Identification of STX-721, an EGFR exon 20 mutant inhibitor with superior selectivity and a potential best-in-class profile
2022 · R. Pagliarini, B.C. Milgram, et al. · European Journal of Cancer · 4
Abstract 1717: MAP4K1 inhibition enhances immune cell activation and anti-tumor immunity in preclinical tumor models
2021 · Kerrie Faia, Alberto Toso, et al. · Cancer Research · 3
Supplementary Methods1 from STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20–Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer Models
2025 · Raymond A. Pagliarini, Jack A. Henderson, et al.
Supplementary Figures1 from STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20–Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer Models
2025 · Raymond A. Pagliarini, Jack A. Henderson, et al.
PDF
Supplementary Tables1 from STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20–Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer Models
2025 · Raymond A. Pagliarini, Jack A. Henderson, et al.
Data from STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20–Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer Models
2025 · Raymond A. Pagliarini, Jack A. Henderson, et al.
Abstract B168: Identification of STX-241, a CNS-penetrant and mutant-selective EGFR inhibitor with activity on osimertinib-resistant C797x mutations
2023 · Raymond A Pagliarini, Benjamin C Milgram, et al. · Molecular Cancer Therapeutics
Abstract B127: Evaluating PRKACA as a therapeutic target for Fibrolamellar Carcinoma
2019 · Stefanie S Schalm, Erin O’Hearn, et al. · Molecular Cancer Therapeutics
Works count: 15
Citation count: 202
H-index: 4
I10-index: 3
Year
Topic
Type